Bifogade filer
PDF
Kalender
| Tid* | ||
| 2025-02-27 | 10:30 | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Kvartalsrapport 2024-Q3 |
| 2024-09-25 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-28 | - | Split WNT 100:1 |
| 2024-05-16 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-02 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-12-12 | - | Extra Bolagsstämma 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-02 | - | Årsstämma |
| 2022-05-06 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-09 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-10 | - | Extra Bolagsstämma 2021 |
| 2021-02-08 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-09 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2020-06-08 | - | Årsstämma |
| 2020-05-19 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-15 | - | Extra Bolagsstämma 2020 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-14 | - | Årsstämma |
| 2019-05-31 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-15 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2019-03-19 | - | Extra Bolagsstämma 2019 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-16 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2018-05-15 | - | Årsstämma |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-09-20 | - | Extra Bolagsstämma 2017 |
| 2017-08-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2017-05-18 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-24 | - | Bokslutskommuniké 2016 |
| 2016-11-25 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-30 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2016-05-27 | - | Årsstämma |
| 2016-05-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-29 | - | Bokslutskommuniké 2015 |
| 2015-11-27 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-10 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2015-06-09 | - | Årsstämma |
| 2015-05-29 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-11-28 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-29 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-12 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2014-06-11 | - | Årsstämma |
| 2014-05-30 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-23 | - | Analytiker möte 2014 |
| 2014-02-28 | - | Bokslutskommuniké 2013 |
| 2013-11-29 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-30 | - | Kvartalsrapport 2013-Q2 |
| 2013-06-19 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2013-06-18 | - | Årsstämma |
| 2013-05-31 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-19 | - | Analytiker möte 2013 |
| 2013-02-25 | - | Extra Bolagsstämma 2013 |
| 2013-02-25 | - | Bokslutskommuniké 2012 |
| 2012-11-13 | - | 15-7 2012 |
| 2012-10-19 | - | Kvartalsrapport 2012-Q3 |
| 2012-10-18 | - | Extra Bolagsstämma 2012 |
| 2012-08-31 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-21 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2012-06-20 | - | Årsstämma |
| 2012-05-31 | - | Kvartalsrapport 2012-Q1 |
| 2012-05-30 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-28 | - | Bokslutskommuniké 2011 |
| 2011-11-25 | - | Extra Bolagsstämma 2011 |
| 2011-11-10 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-31 | - | Kvartalsrapport 2011-Q2 |
| 2011-06-20 | - | X-dag ordinarie utdelning WNT 0.00 SEK |
| 2011-06-17 | - | Årsstämma |
| 2011-05-17 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-28 | - | Bokslutskommuniké 2010 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
WntResearch announces that a poster on the previously communicated positive ad hoc observations from the ongoing clinical phase 2 study NeoFox, will be presented at ESMO Gastrointestinal Cancer Congress (ESMO GI), the leading European congress for gastrointestinal cancer held between June 26-29 in Munich, Germany.
The poster presented at ESMO GI details ad hoc observations from 110 patients in the ongoing NeoFox study, indicating that a three-week pre-operative treatment with Foxy-5 rapidly reduces local tumour spread of colon cancer. Additionally, the poster includes new data on tumour (T)-staging. NeoFox is an open, randomized phase 2 trial in patients with stage II/III colon cancer that compares pre-operative treatment with Foxy-5 to an untreated control group.
The results in brief:
Pre-operative treatment with Foxy-5 was associated with an excellent safety profile.
Histopathological examination of surgically removed tissue suggested an effect of Foxy-5 on the local spread of the primary tumors within 3-4 weeks of treatment:- Fewer patients had perineural invasion of cancer cells
- Fewer patients had venous invasion of cancer cells
- Foxy-5 was associated with TN(M) downstaging
The significance of histologic findings in a neoadjuvant setting in colon cancer is supported by an indirect comparison with neoadjuvant chemotherapy (FOLFOX).
The title of the poster is: "Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase 2 NeoFox study."
WntResearch has redesigned the study following the positive observations to focus on the early pre-operative effects in stage III colon cancer and plans to present initial efficacy data towards the year-end 2024. Final results are expected during 2H 2025.
For further information, please contact:
Per Norlen CEO
E-mail: per.norlen@wntresearch.com
About WntResearch
WntResearch AB (publ) is an oncology biotech company that develops new therapies to prevent cancer metastasis. The company's research is focused on the protein WNT5A, which in preclinical models has been shown to reduce the ability of tumor cells to migrate and spread in the body. WntResearch's drug candidate Foxy-5 is a peptide that mimics the function of WNT5A, with the aim of redcucing mortality by preventing metastasis. Foxy-5 has a unique mechanism of action and has demonstrated a good safety profile with few side effects in clinical trials. Foxy-5's safety and efficacy profile is now being evaluated in patients with stage III colon cancer in the ongoing clinical phase 2 trial NeoFox.
WntResearch's shares are traded on Spotlight Stock Market. For more information, please visit www.wntresearch.com